melanocortin receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-18. Numbers and descriptions here follow the published literature rather than marketing material.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic peptide | Melanocortin receptor agonist family |
| Molecular weight | Approximately 1025 Da | Free base form |
| Appearance | White to off-white powder | Lyophilized product |
| Solubility | Soluble in water | Also dissolves in polar organic solvents |
| Storage temperature | -20 degrees Celsius | Dry and protected from light |
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
IUPAC pointed out that the Berkeley laboratory had already been recognized several times, in the naming of berkelium, californium, and americium, and that the acceptance of the names rutherfordium and seaborgium for elements 104 and 106 should be offset by recognizing JINR's contributions to the discovery of elements 104, 105, and 106. Even after 1997, LBL still sometimes used the name hahnium for element 105 in their own material, doing so as recently as 2014. However, the problem was resolved in the literature as Jens Volker Kratz, editor of Radiochimica Acta, refused to accept papers not using the 1997 IUPAC nomenclature.
== Legal basis == As early as 1905, the Frenchman Viktor Hennecart called for special legislation to regulate the use of X-rays. In England, Sidney Russ (1879-1963) suggested to the British Roentgen Society in 1915 that it should develop its own set of safety standards, which it did in July 1921 with the formation of the British X-Ray and Radium Protection Committee. In the United States, the American X-Ray Society developed its own guidelines in 1922. In the German Reich, a special committee of the German X-Ray Society under Franz Maximilian Groedel (1881-1951), Hans Liniger (1863-1933) and Heinz Lossen (1893-1967) formulated the first guidelines after the First World War. In 1953, the employers' liability insurance associations issued the accident prevention regulation "Use of X-rays in medical facilities" based on the legal basis in § 848a of the Reich Insurance Code (RVG). In the GDR, the Occupational Safety and Health Regulation (ASAO) 950 was in effect from 1954 to 1971. It was replaced by ASAO 980 on April 1, 1971.
High Voltage Engineering Corporation (HVEC) was an American manufacturer of particle accelerators and one of the first venture capital-backed startups. HVEC originated at MIT, where physicist Robert Van de Graaff invented a high-voltage electrostatic particle accelerator and his colleague John Trump miniaturized it for cancer radiotherapy. In 1946, Trump organized a company to manufacture these machines, recruiting Van de Graaff and Denis Robinson as co-founders. Production began in a Cambridge automobile garage. The company's early medical devices gave way to large research accelerators after the Sputnik crisis increased governments' investments in nuclear physics. For two decades, HVEC accelerators were the dominant platform for nuclear physics; in the 1970s, nearly 70 percent of experimental papers relied on HVEC machines. The company built 471 accelerators between 1946 and 1981. They were installed at hospitals, universities, and national laboratories in 30 countries, and some remain in active research use. Using these instruments, HVEC subsidiaries introduced new uses of accelerator beams. Ion Physics Corporation demonstrated that ion implantation could precisely control transistor characteristics, a technique now essential to integrated circuit fabrication. Electronized Chemicals Corporation developed methods to crosslink plastics with electron beams, producing the heat-shrink tubing now ubiquitous in electrical wiring. HVEC was one of the first two startups backed by the American Research & Development Corporation, the first modern venture capital fund.
== Legal status == Ketazolam is a List 3 drug under the Betäubungsmittelgesetz, like almost all benzodiazepines in Germany. Ketazolam is a List II drugs of the Opium Law in the Netherlands. Ketazolam is a Schedule IV drug under the Controlled Substances Act in the US.
Mōri Motonari issued each soldier a bag of rice, fried rice, and mochi, the latter of which was chosen due to its portability, long shelf life, ability to provide high energy in small amounts, and Motonari's personal preference for it. Uesugi Kenshin would prepare massive feasts for his army before battles, known as kachidoki-meshi ("victory cry meals"), featuring delicacies such as "a mountain of rice ... black-boiled abalone, vinegar-washed fish and jellyfish sashimi, soups with seasonal vegetables and dried fish, walnut-roasted duck, simmered sand borer, and more", though Kenshin himself was noted to eat very little. During battles, Kenshin assembled supply convoys called konidatai staffed by peasants, who would deliver supplies and rations to troops. Toyotomi Hideyoshi is said to have regularly distributed food rations out to his officers and soldiers, and kept them well-fed. In one instance, while traveling from Ogaki to Nagahama (a 52 kilometer distance) in 1583, Hideyoshi sent scouts ahead to each village to ask that they prepare rice for Hideyoshi's army; the villages set out rice balls for the soldiers, allowing them to remain fed for the entire trip. In general, Japanese soldiers would bring uchigaibukuro, pouches used to store rice and medicine, into battle with them. They would also eat miso, dried taro stalk, and okayu as part of a soup prepared in a soldier's jingasa.
Sources: en.wikipedia.org
"Explaining the End of the Cold War: A New Historical Consensus?" Journal of Cold War Studies - Volume 4, Number 4, Fall 2002, pp. 60–92 in Project MUSE. Trachtenberg, Marc. "The Marshall Plan as Tragedy." Journal of Cold War Studies 2005 7(1): 135–140. ISSN 1520-3972 Fulltext: in Project MUSE. Walker, J. Samuel. "Historians and Cold War Origins: The New Consensus", in Gerald K. Haines and J. Samuel Walker, eds., American Foreign Relations: A Historiographical Review (1981), 207–236. Watry, David M. Diplomacy at the Brink: Eisenhower, Churchill, and Eden in the Cold War. Baton Rouge: Louisiana State University Press, 2014. ISBN 9780807157183. Westad, Odd Arne, ed. Reviewing the Cold War: Approaches, Interpretations, Theory (2000) essays by scholars. Westad, Odd Arne, "The New International History of the Cold War: Three (Possible) Paradigms," Diplomatic History, 2000, Vol. 24 in EBSCO. Westad, Odd Arne, ed. Reviewing the Cold War: Approaches, Interpretations, Theory (2000) excerpt and text search. Westad, Odd Arne, The Cold War: A World History, Basic Books, 2017. ISBN 0465054935. White, Timothy J. "Cold War Historiography: New Evidence Behind Traditional Typographies" International Social Science Review, (2000). Xia, Yafeng. "The Study of Cold War International History in China: A Review of the Last Twenty Years," Journal of Cold War Studies10#1 Winter 2008, pp. 81–115 in Project MUSE.
=== Stress === Chronic stress can aggravate allergic conditions. This has been attributed to a T helper 2 (TH2)-predominant response driven by suppression of interleukin 12 by both the autonomic nervous system and the hypothalamic–pituitary–adrenal axis. Stress management in highly susceptible individuals may improve symptoms.
The 4n+2 chain of uranium-238 is called the "uranium series" or "radium series", the latter from the first member known when it was named, radium-226. The series terminates with lead-206, 8 alpha decays and 6 beta decays from uranium. The total energy released from uranium-238 to lead-206, including the energy lost to neutrinos, is 51.69 MeV; from californium-250, 68.28 MeV.
Concussion-induced unconsciousness Cerebral ischemia Memory disruption Narcolepsy and cataplexy Seizures and spontaneous convulsions Spinal trauma In human studies, a 0.5 mg dose administered over 14 days improved consciousness in 73% of patients with neurological disturbances. Its ability to stimulate cholinergic and noradrenergic systems suggests promise in treating cognitive dysfunction and sleep disorders. Although it the patent, it said that the strength of the medicine was 4mg per tablet, but in contrast to TRH it can be administered orally and is more resistant to metabolic degradation.
== Characters == Joseph Rouletabille – the young journalist and amateur detective, protagonist. Jean Sainclair – Rouletabille's friend and lawyer, the narrator. Frédéric Larsan – the police detective. Professor Stangerson – the scientist, owner of "Chateau du Glandier". Mademoiselle Mathilde Stangerson – daughter of a famous scientist, the victim. "Father" Jacques – an old servant in the Stangerson family. Robert Darzac – a scientist and Mlle. Stangerson's fiancé. The Green Man – the gamekeeper, disliked by all.
Sources: en.wikipedia.org
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.
It emerged from research on melanotan II. Investigators exploring derivatives observed distinct pharmacological features related to sexual function.
Common names include bremelanotide and PT-141. Chemical databases may also list early development codes and descriptive names.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.